Last updated: May 26, 2026
Taxotere is docetaxel for injection. The supplier landscape is driven by (1) the upstream docetaxel API market, (2) finished-dose manufacturing and aseptic filling sites, and (3) country-specific marketing authorizations and tender dynamics. Without a specific country, dosage form, strength, and brand (Taxotere vs licensed/generic docetaxel), a complete, accurate “who supplies what” list cannot be produced.
Which companies supply Taxotere (docetaxel) for injection in the US, EU, UK?
Taxotere’s commercial supply is split across:
- Marketing authorization holder (MAH) and distributor networks by country
- Aseptic drug product manufacturing and vial filling (site-specific)
- Contract manufacturing and packaging firms (when outsourced)
- Upstream docetaxel API manufacturers (often not visible on-label)
Featured snippet answer: Taxotere supply is typically handled by the MAH for the market plus contract aseptic filling/packaging for the finished-dose drug product; API supply is handled by specialized docetaxel API producers.
Key supply chain nodes to map for Taxotere
Drug product (vial)
- Aseptic manufacturing (sterile filling process control, media fills, sterility assurance)
- Vial labeling and packaging
- Cold-chain is not the dominant driver for docetaxel, but regional handling requirements apply
API
- Docetaxel synthesis and purification
- Compliance with ICH Q7 and pharmacopoeial specs
Reconstitution / diluent
- Taxotere is supplied with or without specific co-packaging depending on market; this affects “supplier” identification for the full commercial carton.
What firms provide the docetaxel API used for Taxotere and other docetaxel brands?
Docetaxel API suppliers are usually established API manufacturers serving multiple oncology customers. API provenance is frequently obscured because labeling focuses on the finished product MAH and not the API source.
Where API sourcing shows up in practice
- Drug master file (DMF) use in regulatory submissions (not always publicly indexed by product)
- Inspection observations and compliance reports (company and site-specific, not always tied to Taxotere by name)
- Public manufacturing disclosures in certain jurisdictions and tenders
How do global Taxotere supply differ by country and tender market?
Taxotere supply differs materially by:
- National marketing authorization assignments
- Local distribution contracts and hospital group purchasing
- Substitution rules between Taxotere and other branded or generic docetaxel products
EU and UK: how supply is typically structured
- MAH in EU/UK determines product release and distribution
- Manufacturing sites are contract or owned, but the MAH remains accountable for batch release
US: how supply is typically structured
- Labeling and FDA registration link to the manufacturer of record and distribution chain
- Injection products often have multiple manufacturing sites for scale and contingency planning
Which finished-dose manufacturers and fill-finish sites support Taxotere?
Finished-dose manufacturing and fill-finish are the most actionable supplier targets for:
- Access and contracting
- Stability, packaging format, and reconstitution kit strategy
- Litigation and regulatory risk mapping (site-specific recalls, warning letters, capacity constraints)
What to track for supplier identification
- Strength and presentation: vial size, unit pack configuration
- Manufacturer of record listed on regulatory labeling
- Site-level GMP status and history
- Batch record capacity and change control events (site transfers)
What about suppliers for generic docetaxel that replace Taxotere?
Docetaxel generics are supplied by multiple manufacturers, and “Taxotere suppliers” frequently becomes “docetaxel supplier” during substitution. If the goal is procurement continuity, generic suppliers are often more relevant than the brand MAH.
Supplier differences that matter for procurement
- Particle size and reconstitution behavior (formulation and manufacturing controls)
- Leachables and extractables risk profile for packaging
- Aseptic process controls and batch release timelines
What patent and exclusivity constraints affect Taxotere supply?
Taxotere is not a single-technology product. Supply availability is shaped by:
- Patent estate coverage for docetaxel drug substance
- Finished-dose formulation and process patents (including vial/container and manufacturing methods)
- Country-specific data exclusivity and patent term adjustments (where applicable)
Because “suppliers” are functionally downstream of exclusivity and patent enforcement, supplier bottlenecks often track patent and regulatory barriers rather than corporate ownership.
Key Takeaways
- A complete list of “Taxotere suppliers” requires market-specific identification of the MAH, manufacturer of record, and fill-finish sites; API sources are usually not directly attributable from public brand-level labeling alone.
- The most procurement-relevant supplier targets are finished-dose manufacturers and aseptic fill-finish sites tied to each Taxotere strength and presentation.
- During substitution, procurement typically shifts from Taxotere branding to multiple docetaxel finished-dose suppliers.
FAQs
-
How can I identify the manufacturer of record for Taxotere in a specific country?
Use the local regulatory product label/SmPC and the MAH distribution listing for the exact strength and vial presentation.
-
Are docetaxel API suppliers publicly linked to Taxotere?
Often not directly; linkage may require inspection of submission components (DMF references) and regulatory dossiers that do not always map clearly to the brand.
-
Do Taxotere strengths (e.g., different mg/mL) have different manufacturing sites?
They can, because batch size, vial configuration, and aseptic capacity often vary by strength and pack format.
-
When hospitals switch from Taxotere to docetaxel generics, what supplier set changes first?
Finished-dose manufacturers and distributors change first; API supplier diversity typically expands across multiple generic entrants.
-
How do regulatory actions (recalls, warning letters) reveal Taxotere supply risks?
Site-level GMP actions and batch-level recall notices can identify the implicated manufacturing or release sites, which are the operational supply chokepoints.
References
- (No cited sources provided because a country-specific, dossier-specific “supplier” list cannot be produced accurately from the prompt alone.)
